|
| Press Releases |
|
 |
|
| Saturday, November 30, 2024 |
|
|
Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate |
| Hua Medicine (the 'Company', HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China BioMed Innovation and Investment Conference (CBIIC). more info >> |
|
|
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC |
| Hua Medicine (the 'Company', HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which dorzagliatin improves the β-cell glucose sensitivity at the 9th China BioMed Innovation and Investment Conference (CBIIC). more info >> |
|
| Friday, October 25, 2024 |
|
|
Founder of Hua Medicine Dr. Chen Li was awarded the 'C.C. Tan Life Science Industrialization Award' |
| The 17th C.C. Tan Life Science Award ceremony was held at Shenyang Pharmaceutical University on October 9th. Dr. Chen Li, Founder and Chief Executive Officer of Hua Medicine, was awarded the C.C. Tan Life Science Industrialization Award . more info >> |
|
| Friday, August 30, 2024 |
|
|
Hua Medicine Announces 2024 Interim Results |
| Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2024 (the "Reporting Period"), and the Company's business progress for the first half of the year and business outlook. more info >> |
|
| Friday, August 25, 2023 |
|
|
Hua Medicine Announces 2023 Interim Results |
| First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. more info >> |
|
| Monday, October 10, 2022 |
|
|
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China |
| Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October 8th for two indications more info >> |
|
| Tuesday, June 7, 2022 |
|
|
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022 |
| Hua Medicine (the "Company", stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. more info >> |
|
| Friday, May 13, 2022 |
|
|
Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine |
| Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin more info >> |
|
| Thursday, March 17, 2022 |
|
|
Hua Medicine Announces 2021 Annual Results |
| Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period"). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin. more info >> |
|
| Sunday, September 26, 2021 |
|
|
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin |
| Hua Medicine (2552.HK) announced that at the 6th China BioMed Innovation & Investment Conference (CBIIC), Professor Jianhua MA, Director, Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society, as one of the principal researchers presented the results from a clinical study called DREAM, which showed that dorzagliatin, a glucokinase activator and a first-in-class investigational drug of Hua Medicine, may make progress in diabetes remission. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Combat Holiday Stress and Protect Your Immunity with LAC This Christmas! 
Jan 3, 2025 22:55 HKT/SGT
|
|
|
Galaxy Payroll Group Limited and People Intelligence Singapore Pte. Ltd. Announce Strategic Partnership
Jan 3, 2025 20:41 JST
|
|
|
Veganuary for Pets
Jan 3, 2025 07:00 HKT/SGT
|
|
|
Asia's Flagship Toy Fair Kicks Off 2025 Trade Shows
Jan 2, 2025 18:37 HKT/SGT
|
|
|
SPRG Steps Confidently into its 30th Year of Development
Jan 2, 2025 16:58 HKT/SGT
|
|
|
Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy
Jan 2, 2025 10:52 HKT/SGT
|
|
|
AEM Appoints Chief Financial Officer
Jan 2, 2025 08:40 HKT/SGT
|
|
|
Capital Revo Receives Prestigious Industry Award for Excellence in Financial Services
Jan 1, 2025 07:00 HKT/SGT
|
|
|
Atlas Lithium Accelerates Production Readiness with Key Executive Appointments
Dec 31, 2024 07:45 HKT/SGT
|
|
|
World's first high-standard negative-pressure isolation ward built with MiC technology completes historical mission
Dec 30, 2024 20:04 HKT/SGT
|
|
|
Hola Prime Establishes Industry's First Dedicated Risk Compliance Team
Dec 30, 2024 20:00 HKT/SGT
|
|
|
The Bilingual Book Company Launches New, Innovative Bilingual Audiobook App
Dec 27, 2024 22:30 HKT/SGT
|
|
|
Annual Surge of 37% in Legal and Compliance Job Roles while overall hiring drops 6% in Singapore: foundit Insights Tracker
Dec 27, 2024 15:20 HKT/SGT
|
|
|
Gruelling Challenge Awaits TGR In Saudi Arabia
Dec 27, 2024 15:20 JST
|
|
|
The General Incorporated Association Generative AI Japan Announces the Winners of the Japan Generative AI Award 2024
Dec 27, 2024 11:00 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
